首页 | 本学科首页   官方微博 | 高级检索  
检索        

视网膜静脉阻塞患者血清同型半胱氨酸水平检测的临床意义
引用本文:张愉,权青云,孙鹃,张贵云.视网膜静脉阻塞患者血清同型半胱氨酸水平检测的临床意义[J].现代检验医学杂志,2018,0(1):118-120.
作者姓名:张愉  权青云  孙鹃  张贵云
作者单位:武警陕西省总队医院干部病房,西安 710054
摘    要:目的 讨论视网膜静脉阻塞(retinal vein occlusion,RVO)患者血浆同型半胱氨酸(homocysteine,Hcy)水平的变化,以研究血浆Hcy升高是否是RVO的危险因素,为治疗和预防该病提供客观依据。方法 采用病例对照研究,收集65例经过统一眼科检查标准确诊RVO且经过系统疾病排除标准筛选的患者作为病例组,其中视网膜中央静脉阻塞(central retinal vein occlusion,CRVO)患者46例,视网膜分支静脉阻塞(branch retinal vein occlusion,BRVO)患者19例; 同期健康体检且既往无眼底血管性疾病病史者65例作为对照组,两组年龄、性别无差异。检测血浆Hcy含量后作统计学比较。结果 RVO病例组的血浆Hcy均值较对照组显著升高(t=6.192,P<0.05)。病例组中CRVO及BRVO患者的血浆Hcy比较差异无统计学意义(t=1.536,P<0.05)。结论 血浆Hcy为RVO的危险因素,降低Hcy的药物可以用于RVO的预防和治疗中。

关 键 词:视网膜静脉阻塞  同型半胱氨酸  危险因素

Clinical Observation of the Relationship between Retinal Vein Occlusion and Homocysteine
ZHANG Yu,QUAN Qing-yun,SUN Juan,ZHANG Gui-yun.Clinical Observation of the Relationship between Retinal Vein Occlusion and Homocysteine[J].Journal of Modern Laboratory Medicine,2018,0(1):118-120.
Authors:ZHANG Yu  QUAN Qing-yun  SUN Juan  ZHANG Gui-yun
Institution:Wards for Officers,Shaanxi Armed Police Corps Hospital,Xi'an 710054,China
Abstract:Abstract:Objective The discussion of plasma homocysteinein retinal vein occlusion(homocysteine,Hcy)level changes,to study whether elevated plasma Hcy is a risk factor for RVO, and provide objective basis for theprevention and treatment of the disease.Methods A case-control study of 65 cases were collected after unified ophthalmic examinationstandard diagnosis of RVO and after disease screening criteria of patients as case group central retinal vein occlusion(CRVO)in 46 patients,branch retinalvein occlusion(BRVO)in 19 healthy people],and no previous history of retinalvascular diseases.65 cases as the control group,the two groups showed no significant difference in age and sex.The content of plasma Hcy after statistical comparison detection.Results The mean plasma Hcy in the RVO case group was significantly higher than that in the control group(t=6.192,P<0.05).There was no significant difference in plasma Hcy index betweenCRVO and BRVO patients in the case group(t=1.536,P>0.05).ConclusionPlasma Hcy is a risk factor for RVO,and a drug that reduces Hcy canbe used in the prevention and treatment of RVO.
Keywords:
本文献已被 CNKI 等数据库收录!
点击此处可从《现代检验医学杂志》浏览原始摘要信息
点击此处可从《现代检验医学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号